Roche (QX) Aktie - RHHBY

Roche Holdings Ltd AG (QX) (RHHBY) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Current Price

51,90

( -0,23% )

Gebot

51,80

Fragen

52,37

Volumen

1.558.790

Durchschnittliches Volumen (3 Mio.)

US$ 1.004.644

Finanzvolumen

US$ 81.039.188

51,80 Tagesbereich 52,42

37,51 52-Wochen-Bereich 60,85

Marktkapitalisierung

41,293B

Unternehmenswert

293,374B

Handelsende

52,02

Handelsbeginn

52,38

Letzte Trade

686

51.91

(formt)

Letzter Handelszeitpunkt

VWAP

51,9885

Erlöse (LTM)

63,36B

Nettogewinn (LTM)

12,88B

Ausgegebene Aktien

795.617.637

Streubesitz (%)

82,07%

Institutioneller Besitz (%)

19,71%

Dividendenrendite (LTM)

9,8 (3,11%)

Kurs-Gewinn-Verhältnis

21,23

Kurs-Umsatz-Verhältnis (KUV)

4,29

Gewinn pro Aktie (EPS)

16,04

Beta

0,34

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases... Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland. Mehr anzeigen

Sektor

Branche

Website

www.roche.com

Hauptsitz

Basel, Switzerland

Gegründet

1896

Roche Holdings Ltd AG (QX) is listed in the sector of the OTC Markets with ticker RHHBY. The last closing price for Roche (QX) was US$52,02. Over the last year, Roche (QX) shares have traded in a share price range of US$ 37,51 to US$ 60,85.

Roche (QX) currently has 795.617.637 shares in issue. The market capitalisation of Roche (QX) is US$41,29 billion. Roche (QX) has a price to earnings ratio (PE ratio) of 21.23.

Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC

Five oral presentations in a Featured Research Session will highlight trontinemab, including new long-term data from Phase Ib/IIa Brainshuttle...

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer

Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer...

FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

The filing application is based on improvements seen across key efficacy endpoints from the global Phase III SatraGO-1 and SatraGO-2 studies...

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple SclerosisBioMedWire Editorial Coverage: Multiple...

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis (“MS”...

FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma

– Filing acceptance based on data from the Phase III SUNMO study where subcutaneous Lunsumio VELO plus Polivy demonstrated a 59% reduction in risk...

FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer

Filing acceptance is based on the Phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50...

Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies

Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and...

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Strategic collaboration combines Nurix’s leadership in targeted protein degradation with Roche’s portfolio of...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0.21	0.40626813697	51.69	52.79	50.9	1753146	51.90146201	DR
4	0.3701	0.718223788519	51.5299	53.4967	48.94	1800125	51.17553017	DR
12	0.97	1.90457490673	50.93	53.54	48.1	2144973	51.21301485	DR
26	-1.77	-3.29793180548	53.67	60.85	47.05	2366215	52.99540118	DR
52	10.95	26.7399267399	40.95	60.85	37.51	2129851	49.57165545	DR
156	14.66	39.3662728249	37.24	60.85	29.2	2103310	40.92225812	DR
260	3.4	7.01030927835	48.5	60.85	27.95	1893816	41.45116594	DR

RHHBY - Frequently Asked Questions (FAQ)

What is the current Roche Holdings Ltd AG (QX) share price?

The current share price of Roche Holdings Ltd AG (QX) is US$ 51,90

How many Roche Holdings Ltd AG (QX) shares are in issue?

Roche Holdings Ltd AG (QX) has 795.617.637 shares in issue

What is the market cap of Roche Holdings Ltd AG (QX)?

The market capitalisation of Roche Holdings Ltd AG (QX) is USD 41,29B

What is the 1 year trading range for Roche Holdings Ltd AG (QX) share price?

Roche Holdings Ltd AG (QX) has traded in the range of US$ 37,51 to US$ 60,85 during the past year

What is the PE ratio of Roche Holdings Ltd AG (QX)?

The price to earnings ratio of Roche Holdings Ltd AG (QX) is 21,23

What is the cash to sales ratio of Roche Holdings Ltd AG (QX)?

The cash to sales ratio of Roche Holdings Ltd AG (QX) is 4,29

What is the registered address of Roche Holdings Ltd AG (QX)?

The registered address for Roche Holdings Ltd AG (QX) is Grenzacherstrasse 124, Basel, Basel-Stadt, 4070

What is the Roche Holdings Ltd AG (QX) website address?

The website address for Roche Holdings Ltd AG (QX) is www.roche.com

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Roche Holdings Ltd AG (QX) (RHHBY)

Roche Holdings Ltd AG (QX) (RHHBY) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über Roche Holdings Ltd AG (QX)

RHHBY Neueste Nachrichten

Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer

FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma

FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer

Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer

FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma

FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer

Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies

RHHBY - Frequently Asked Questions (FAQ)

RHHBY Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Roche Holdings Ltd AG (QX) (RHHBY)

Roche Holdings Ltd AG (QX) (RHHBY) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über Roche Holdings Ltd AG (QX)

RHHBY Neueste Nachrichten

Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer

FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma

FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer

Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer

FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma

FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer

Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies

RHHBY - Frequently Asked Questions (FAQ)

RHHBY Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich GRATIS und erhalten Sie:

Werbung entfernen